WT1 peptide
Wilms tumor 1 (WT1) antigen-derived peptide RMFPNAPYL
9 Amino Acids · MW: 1179.4 Da
Amino Acids
9
Molecular Weight
1179.4 Da
Half-life
minutes to hours
Research Score
4.2
Studies
50
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is WT1 peptide?
A WT1-derived 9-mer peptide used in peptide-vaccine strategies for leukemias and solid tumors. It is intended to generate HLA-restricted cytotoxic T-cell responses against WT1-positive cancer cells.
Key Benefits & Mechanisms
WT1-targeted immunity
widely studied in leukemia
vaccine-platform compatible
favorable safety profile
Research Summary
WT1 peptide vaccines have been investigated in AML, MDS, ovarian cancer, and mesothelioma. Results consistently show immunogenicity, with clinical responses in subsets of patients and stronger rationale in combination approaches.
Related Peptides
GV1001
Human telomerase reverse transcriptase (hTERT) 611-626 peptide GV1001
A telomerase-derived 16-mer peptide developed as a cancer vaccine antigen. It is designed to trigger T-cell responses against hTERT-expressing tumors.
Cancer ResearchNelipepimut-S
HER2/neu-derived peptide vaccine Nelipepimut-S (E75; KIFGSLAFL)
A 9-mer HLA-A2/A3-restricted peptide from HER2/neu used as a vaccine antigen. It aims to expand cytotoxic T-cell responses against HER2-positive tumors.
Cancer ResearchSurvivin 2B peptide
Survivin 2B peptide (LMLGEFLKL)
A survivin-derived HLA-A24-restricted epitope investigated as a peptide vaccine antigen. It targets survivin, a frequently overexpressed inhibitor of apoptosis in tumors.
Cancer ResearchTumstatin
Collagen IV Alpha-3 NC1 Domain (Tumstatin)
Tumstatin is a collagen IV-derived fragment that inhibits angiogenesis and can induce apoptosis in endothelial cells. It is studied as a selective suppressor of pathologic vessel growth in tumor biology.
Cancer Research